An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Cancer Research.” The article titled “A Novel MYCN-Specific Antigen Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma. The article is about the anti-tumor effects obtained in preclinical studies of BIOGENERA’s new drug BGA002, for the treatment of Neuroblastoma with MYCN gene amplification. Specifically, the study conducted showed that the drug BGA002 acts through overcoming the “barriers” created by the Neuroblastom through deregulation of the activity of the mitochondria of the tumor cells.
The publication is titled “A Novel MYCN-Specific Antigen Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma” (Montemurro et. Al, Cancer Research, Dec. 2019).
Link to article:
https://pubmed.ncbi.nlm.nih.gov/31615807/
Download article:
